BioSpace News Archive

FOXO Technologies Inc. announced that the United States Patent & Trademark Office has provided an Issue Notification for a key patent utilizing a machine learning model trained to determine a biochemical state and/or medical condition using DNA epigenetic data to enable the commercialization of epigenetic biomarkers.

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) held October 13-15 in Phoenix.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”) today announced that data from 14 studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2-5 in Philadelphia, Pennsylvania and at the 2023 American College of Rheumatology Convergence (ACR), taking place November 10-15 in San Diego, California.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Biomerica, Inc., a global provider of advanced medical diagnostic and therapeutic products reported financial results for the first quarter of fiscal 2024 ended August 31, 2023.

AIVITA Biomedical, Inc. announced that chief executive officer Hans S. Keirstead, Ph.D. will moderate a keynote panel and deliver a talk at the World Vaccine Congress Europe, taking place October 16-19 in Barcelona, Spain.

Foresee Pharmaceuticals, announces that the first patient has been dosed in the Casppian Phase 3 registration study.

Cerevel Therapeutics announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open.

Meiji Seika Pharma Co., Ltd. announced that positive findings from the phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, in patients with plaque psoriasis conducted in the United States and Canada were presented on 12 October at the European Association of Dermatology and Venereology Congress 2023 held in Berlin.

Invitation to attend Vitrolife AB conference call regarding presentation of the interim report Q3, 2023. The presentation will be held in English.